Similar Characteristics of Endometrial and Endometriotic Epithelial Cells

Epithelial-mesenchymal transition (EMT) is characterized by the loss of epithelial and acquisition of mesenchymal cell characteristics. Our aim was to assess the epithelial phenotype in the pathogenesis of endometriosis with epithelial and mesenchymal markers. We used 2 structural (keratin-18, -19 [K18, K19]), 1 membrane-associated (mucin-1 [MUC1]), and 2 mesenchymal proteins (vimentin; zinc finger E-box-binding homeobox 1, [ZEB1]) to compare epithelial and mesenchymal characteristics in eutopic endometrium with the 3 endometriotic entities, peritoneal, ovarian, and deep infiltrating endometriosis (DIE). Quanti-tation showed no differences for K18, K19, and MUC1 between endometrium with and without endometriosis. Also, K18 was not different between endometrium and endometriotic lesions. In contrast, K19 and MUC1 were modestly but significantly decreased in the endometriotic lesions compared to endometrium. However, the maintained expression of epithelial markers in all investigated tissues, regardless of the pathological condition, clearly indicates no loss of the epithelial phenotype. This is further supported by the reduced presence of epithelial vimentin in endometriotic lesions which is in contrast to an increase in stromal vimentin in ectopic endometrium, especially in ovarian endometriosis. The ZEB1 increase in endometriotic lesions, especially in DIE, on the other hand suggests a role of partial EMT in the development of endometriotic lesions, possibly connected with the gain of invasive capabilities or stemness. Taken together, although we found some hints for at least a partial EMT, we did not observe a severe loss of the epithelial cell phenotype. Thus, we propose that EMT is not a main factor in the pathogenesis of endometriosis. Similar content being viewed by others

Clement PB. The pathology of endometriosis: a survey of the many faces of a common disease emphasizing diagnostic pitfalls and unusual and newly appreciated aspects. Adv Anat Pathol. 2007;14(4):241–260. Bulun SE. Endometriosis. N Engl J Med. 2009;360(3):268–279. Sampson JA. Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927;14:422–469 Nisolle M, Donnez J. Peritoneal endometriosis, ovarian endome-triosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil Steril. 1997;68(4):585–595. Thompson EW, Newgreen DF. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res. 2005;65(14):5991–5995. Chui MH. Insights into cancer metastasis from a clinicopathologic perspective: epithelial-mesenchymal transition is not a necessary step. Int J Cancer. 2013;132(7):1487–1495. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890. Tarin D. Role of the host stroma in cancer and its therapeutic significance. Cancer Metastasis Rev. 2013;32(3-4):553–566. Kriz W, Kaissling B, Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest. 2011; 121(2):468–474. Guarino M, Tosoni A, Nebuloni M. Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition. Hum Pathol. 2009;40(10):1365–1376. Mazzucchelli L. Protein S100A4: too long overlooked by pathologists? Am J Pathol. 2002;160(1):7–13. Zhang P, Sun Y, Ma L. ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 2015;14(4):481–487. Bartley J, Jülicher A, Hotz B, Mechsner S, Hotz H. Epithelial to mesenchymal transition (EMT) seems to be regulated differently in endometriosis and the endometrium. Arch Gynecol Obstet. 2014;289(4):871–881. Matsuzaki S, Darcha C. Epithelial to mesenchymal transition-like and mesenchymal to epithelial transition-like processes might be involved in the pathogenesis of pelvic endometriosis. Hum Reprod. 2012;27(3):712–721. Young VJ, Brown JK, Saunders PT, Duncan WC, Horne AW. The peritoneum is both a source and target of TGF-b in women with endometriosis. PLoS One. 2014;9(9):e106773. Furuya M, Masuda H, Hara K, et al. ZEB1 expression is a potential indicator of invasive endometriosis. Acta Obstet Gynecol Scand. 2017;96(9):1128–1135. Baártek J, Baártkovaá J, Taylor-Papadimitriou J, et al. Differential expression of keratin 19 in normal human epithelial tissues revealed by monospecific monoclonal antibodies. Histochem J. 1986;18(10):565–575. Kruitwagen RF, Poels LG, Willemsen WN, et al. Immunocyto-chemical markerprofile of endometriotic epithelial, endometrial epithelial, and mesothelial cells: a comparative study. Eur J Obstet Gynecol Reprod Biol. 1991;41(3):215–223. Stewart CJ, Crook ML, Lacey J, Louwen K. Cytokeratin 19 expression in normal endometrium and in low-grade endome-trioid adenocarcinoma of the endometrium. Int J Gynecol Pathol. 2011;30(5):484–491. Haas D, Chvatal R, Habelsberger A, Wurm P, Schimetta W, Oppelt P. Comparison of revised American Fertility Society and ENZIAN staging: a critical evaluation of classifications of endo-metriosis on the basis of our patient population. Fertil Steril. 2011;95(5):1574–1578. Konrad L, Scheiber JA, Völck-Badouin E, et al. Alternative splicing of TGF-betas and their high-affinity receptors TbRI, TbRII and TbRIII (Betaglycan) reveal new variants in human prostatic cells. BMC Genomics 2007;8:318. Dharmaraj N, Chapela PJ, Morgado M, et al. Expression of the transmembrane mucins, MUC1, MUC4 and MUC16, in normal endometrium and in endometriosis. Hum Reprod. 2014;29(8): 1730–1738. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002;40(5):403–439. Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem Cell Biol. 2008;129(6):705–733. Van der Linden PJ, Dunselman GA, de Goeij AF, van der Linden EP, Evers JL, Ramaekers FC. Epithelial cells in peritoneal fluid—of endometrial origin? Am J Obstet Gynecol. 1995; 173(2):566–570. Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008;70:431–457. Thathiah A, Carson DD. MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17. Biochem J. 2004;382(pt 1): 363–373. Guaita S, Puig I, Franci C, et al. Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem. 2002;277(42): 39209–39216. Hey NA, Li TC, Devine PL, Graham RA, Saravelos H, Aplin JD. MUC1 in secretory phase endometrium: expression in precisely dated biopsies and flushings from normal and recurrent patients. Hum Reprod. 1995;10(10):2655–2662. Budiu RA, Diaconu I, Chrissluis R, Dricu A, Edwards RP, Vlad AM. A conditional mouse model for human MUC1-positive endometrio-sis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells. Dis Model Mech. 2009;2(11-12):593–603. Drapkin R, Crum CP, Hecht JL. Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence of a link between epithelial phenotype and neoplasia. Hum Pathol. 2004;35(8):1014–1021. Kidd ME, Shumaker DK, Ridge KM. The role of vimentin inter-mediate filaments in the progression of lung cancer. Am J Respir Cell Mol Biol. 2014;50(1):1–6. Chai JY, Modak C, Mouazzen W, Narvaez R, Pham J. Epithelial or mesenchymal: Where to draw the line? Biosci Trends. 2010; 4(3):130–142. Nisolle M, Casanas-Roux F, Donnez J. Coexpression of cytokeratin and vimentin in eutopic endometrium and endometriosis throughout the menstrual cycle: evaluation by a computerized method. Fertil Steril. 1995;64(1):69–75. Song IO, Hong SR, Huh Y, Yoo KJ, et al. Expression of vimentin and cytokeratin in eutopic and ectopic endometrium of women with adenomyosis and ovarian endometrioma. Am J Reprod Immunol. 1998;40(1):26–31. Sanghvi-Shah R, Weber GF. Intermediate filaments at the junction of mechanotransduction, migration, and development. Front Cell Dev Biol. 2017;5:81. Vosse BA, Seelentag W, Bachmann A, Bosman FT, Yan P. Back-ground staining of visualization systems in immunohistochemistry: comparison of the Avidin-Biotin Complex system and the EnVision+ system. Appl Immunohistochem Mol Morphol. 2007;15(1):103–107. Krebs AM, Mitschke J, Lasierra Losada M, et al. The EMT-activator Zeb1 is a key factor for cell plasticitiy and pormotes metastasis in pancreatic cancer. Nat Cell Biol. 2017;19(5):518–529. Konrad L, Kortum J, Nabham R, et al. Composition of the stroma in the human endometrium and endometriosis. Reprod Sci. 2017; doi:10.1177/1933719117734319 Goscinski MA, Xu R, Zhou F, et al. Nuclear, cytoplasmic, and stromal expression of ZEB1 in squamous and small cell carcinoma of the oesophagus. APMIS. 2015;123(12):1040–1047. Spaderna S, Schmalhofer O, Hlubek F, et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006;131(3): 830–840. Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166(1):21–45. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Konrad, L., Gronbach, J., Horné, F. et al. Similar Characteristics of Endometrial and Endometriotic Epithelial Cells. Reprod. Sci. 26, 49–59 (2019). https://doi.org/10.1177/1933719118756745 Published: Version of record: Issue date: DOI: https://doi.org/10.1177/1933719118756745